{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:02:25Z","timestamp":1762452145194,"version":"build-2065373602"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ph.D. Research Startup Fund of Lishui University","award":["QD2318, QD2329"],"award-info":[{"award-number":["QD2318, QD2329"]}]},{"name":"Undergraduate Training Program for Innovation and Entrepreneurship","award":["202310352025"],"award-info":[{"award-number":["202310352025"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10822-025-00650-z","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T15:04:33Z","timestamp":1755615873000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structure-based drug design of small molecule AKT1 inhibitors to treat glioma"],"prefix":"10.1007","volume":"39","author":[{"given":"Xiuzhi","family":"Jia","sequence":"first","affiliation":[]},{"given":"Qinglian","family":"Han","sequence":"additional","affiliation":[]},{"given":"Xiaoqun","family":"Ma","sequence":"additional","affiliation":[]},{"given":"Zhongwen","family":"Sun","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"issue":"2","key":"650_CR1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJM200101113440207","volume":"344","author":"LM DeAngelis","year":"2001","unstructured":"DeAngelis LM (2001) Brain tumors. N Engl J Med 344(2):114. https:\/\/doi.org\/10.1056\/NEJM200101113440207","journal-title":"N Engl J Med"},{"issue":"1","key":"650_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01513-z","volume":"21","author":"K Yang","year":"2022","unstructured":"Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, Dai Z, Zhang X, Zhang L, Peng Y, Ye W, Zeng W, Liu Z, Cheng Q (2022) Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer 21(1):39. https:\/\/doi.org\/10.1186\/s12943-022-01513-z","journal-title":"Mol Cancer"},{"issue":"8","key":"650_CR3","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"650_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102029","volume":"87","author":"M Weller","year":"2020","unstructured":"Weller M, Le Rhun E (2020) How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat Rev 87:102029. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102029","journal-title":"Cancer Treat Rev"},{"issue":"22","key":"650_CR5","doi-asserted-by":"publisher","first-page":"33440","DOI":"10.18632\/oncotarget.7961","volume":"7","author":"X Li","year":"2016","unstructured":"Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L (2016) PI3K\/Akt\/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 7(22):33440. https:\/\/doi.org\/10.18632\/oncotarget.7961","journal-title":"Oncotarget"},{"issue":"13","key":"650_CR6","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.2174\/0929867323666161223150242","volume":"24","author":"L Lin","year":"2017","unstructured":"Lin L, Cai J, Jiang C (2017) Recent advances in targeted therapy for glioma. Curr Med Chem 24(13):1365. https:\/\/doi.org\/10.2174\/0929867323666161223150242","journal-title":"Curr Med Chem"},{"issue":"11","key":"650_CR7","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","volume":"14","author":"MH Cohen","year":"2009","unstructured":"Cohen MH, Shen YL, Keegan P, Pazdur R (2009) Fda drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14(11):1131. https:\/\/doi.org\/10.1634\/theoncologist.2009-0121","journal-title":"Oncologist"},{"issue":"8","key":"650_CR8","first-page":"2231","volume":"48","author":"PA Humphrey","year":"1988","unstructured":"Humphrey PA, Wong AJ, Vogelstein B, Friedman HS, Werner MH, Bigner DD, Bigner SH (1988) Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48(8):2231","journal-title":"Cancer Res"},{"issue":"2","key":"650_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ijrobp.2010.01.070","volume":"80","author":"JH Uhm","year":"2011","unstructured":"Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn PJ, Schaefer PL, Dakhill SR, Jaeckle KA (2011) Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo\/North Central Cancer Treatment Group study N0074. Int J Radiat Oncol Biol Phys 80(2):347. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.01.070","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"650_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11060-009-0067-2","volume":"98","author":"DM Peereboom","year":"2010","unstructured":"Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, Suh JH, Toms SA, Vogelbaum MA, Weil RJ, Elson P, Barnett GH (2010) Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 98(1):93. https:\/\/doi.org\/10.1007\/s11060-009-0067-2","journal-title":"J Neurooncol"},{"issue":"2","key":"650_CR11","first-page":"155","volume":"1","author":"JP Robinson","year":"2011","unstructured":"Robinson JP, Vanbrocklin MW, McKinney AJ, Gach HM, Holmen SL (2011) Akt signaling is required for glioblastoma maintenance in vivo. Am J Cancer Res 1(2):155","journal-title":"Am J Cancer Res"},{"issue":"6","key":"650_CR12","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1158\/1535-7163.MCT-06-0091","volume":"5","author":"L de la Pena","year":"2006","unstructured":"de la Pena L, Burgan WE, Carter DJ, Hollingshead MG, Satyamitra M, Camphausen K, Tofilon PJ (2006) Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol Cancer Ther 5(6):1504. https:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0091","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"650_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11060-019-03243-7","volume":"144","author":"TJ Kaley","year":"2019","unstructured":"Kaley TJ, Panageas KS, Mellinghoff IK, Nolan C, Gavrilovic IT, DeAngelis LM, Abrey LE, Holland EC, Lassman AB (2019) Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. J Neurooncol 144(2):403. https:\/\/doi.org\/10.1007\/s11060-019-03243-7","journal-title":"J Neurooncol"},{"issue":"5","key":"650_CR14","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1021\/jm301762v","volume":"56","author":"M Addie","year":"2013","unstructured":"Addie M, Ballard P, Buttar D, Crafter C, Currie G, Davies BR, Debreczeni J, Dry H, Dudley P, Greenwood R, Johnson PD, Kettle JG, Lane C, Lamont G, Leach A, Luke RWA, Morris J, Ogilvie D, Page K, Pass M, Pearson S, Ruston L (2013) Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases. J Med Chem 56(5):2059. https:\/\/doi.org\/10.1021\/jm301762v","journal-title":"J Med Chem"},{"issue":"11","key":"650_CR15","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nrd1549","volume":"3","author":"DB Kitchen","year":"2004","unstructured":"Kitchen DB, Decornez H, Furr JR, Bajorath J (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 3(11):935. https:\/\/doi.org\/10.1038\/nrd1549","journal-title":"Nat Rev Drug Discov"},{"key":"650_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13321-015-0069-3","author":"D Bajusz","year":"2015","unstructured":"Bajusz D, Racz A, Heberger K (2015) Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? J Cheminform. https:\/\/doi.org\/10.1186\/s13321-015-0069-3","journal-title":"J Cheminform"},{"issue":"16","key":"650_CR17","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/jcc.10349","volume":"24","author":"Y Duan","year":"2003","unstructured":"Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, Yang R, Cieplak P, Luo R, Lee T, Caldwell J, Wang J, Kollman P (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 24(16):1999. https:\/\/doi.org\/10.1002\/jcc.10349","journal-title":"J Comput Chem"},{"issue":"9","key":"650_CR18","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25(9):1157. https:\/\/doi.org\/10.1002\/jcc.20035","journal-title":"J Comput Chem"},{"issue":"5","key":"650_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden S, Ryde U (2015) The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10(5):449. https:\/\/doi.org\/10.1517\/17460441.2015.1032936","journal-title":"Expert Opin Drug Discov"},{"key":"650_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/srep42717","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. https:\/\/doi.org\/10.1038\/srep42717","journal-title":"Sci Rep"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00650-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-025-00650-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00650-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:56:18Z","timestamp":1762451778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-025-00650-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["650"],"URL":"https:\/\/doi.org\/10.1007\/s10822-025-00650-z","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"type":"print","value":"0920-654X"},{"type":"electronic","value":"1573-4951"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"69"}}